Marine Drugs (Jul 2022)

Monocaprin Enhances Bioavailability of Fucoxanthin in Diabetic/Obese KK-<i>A<sup>y</sup></i> Mice

  • Kodai Nagata,
  • Naoki Takatani,
  • Fumiaki Beppu,
  • Aya Abe,
  • Etsuko Tominaga,
  • Tomohisa Fukuhara,
  • Makoto Ozeki,
  • Masashi Hosokawa

DOI
https://doi.org/10.3390/md20070446
Journal volume & issue
Vol. 20, no. 7
p. 446

Abstract

Read online

Fucoxanthin is a marine carotenoid found in brown seaweeds and several microalgae. It has been reported that fucoxanthin has health benefits such as anti-obesity and anti-diabetic effects. To facilitate fucoxanthin applications in the food industry, it is important to improve its low bioavailability. We attempted the combined feeding of fucoxanthin-containing seaweed oil (SO) and monocaprin in a powder diet and analyzed the fucoxanthin metabolite contents in the liver, small intestine and serum of diabetic/obese KK-Ay mice. After 4 weeks of feeding with the experimental diets, the serum fucoxanthinol concentrations of the mice fed 0.2% SO and 0.5% monocaprin were higher than those of the 0.2% SO-fed mice. Furthermore, fucoxanthinol accumulation in the liver and small intestine tended to increase in a combination diet of 0.2% SO and 0.125–0.5% monocaprin compared with a diet of 0.2% SO alone, although amarouciaxanthin A accumulation was not different among the 0.2% SO-fed groups. These results suggest that a combination of monocaprin with fucoxanthin-containing SO is an effective treatment for improving the bioavailability of fucoxanthin.

Keywords